688428 InnoCare Pharma

Watchlist

12.84
-0.07-0.54%

Market Closed Dec 19 15:00 CST

22.63BMarket Cap-60.28P/E (TTM)

About InnoCare Pharma Company

The company is a commercialized biomedical high-tech company. It was co-founded in 2015 by Dr. Cui Jisong, who has rich experience in new drug development and enterprise management, and Academician Shi Yigong, a world-famous structural biologist. We develop innovative drugs for patients with malignant tumors and autoimmune diseases, so that innovative results can benefit more patients. The company is a high-tech innovative biomedical enterprise with excellent independent research and development capabilities as the core driving force. It has comprehensive R&D, production and commercialization capabilities, focuses on fields such as tumors and autoimmune diseases where there are huge unmet clinical needs, and develops first-of-its-kind or best-in-class drugs with breakthrough potential in the global market. Main products: obutinib, ICP-B04, ICP-248, ICP-B02, ICP-490, ICP-B05, ICP-332, ICP-488, ICP-B02, ICP-923, ICP-723,, ICP-192, etc. ICP-189

Company Profile

Short Name-A诺诚健华

Company NameInnocare Pharma Limited

Listing DateSep 21, 2022

Issue Price11.03

Shares Offered264.65M share(s)

FoundedNov 3, 2015

Chairmanjisong cui

Legal Representativejisong cui

General Managerjisong cui

Secretarybei yuan

Employees1089

ProvinceCayman Islands (the)

Phone(86)1066609999

Office AddressBuilding 8, No. 8, Shengyuan Road, Zhongguancun Life Science Park, Changping District, Beijing

Zip Code102206

Registered AddressOgier Global (Cayman) Limited's offices 89 Nexus Way Camana Bay Grand Cayman, KY1-9009 Cayman Islands

Fax(86)1060702992

Emailinfo@innocarepharma.com

Websitehttp://www.innocarepharma.com

BusinessNuochengjianhua is an innovative biomedical enterprise with excellent independent research and development capabilities as the core driving force. It has comprehensive R&D and commercialization capabilities, focuses on fields such as tumors and autoimmune diseases where there are huge unmet clinical needs, and develops best-in-class or first-of-its-kind drugs with breakthrough potential in the global market.